Mailman 3 December 2003 - NumPy-Discussion

meshless methods
by Jerome Figueroa Dec. 4, 2003

Dec. 4, 2003

Hi, I would like to ask if anyone has worked on meshless methods or any of the below mentioned using python (with numpy or any other python open source tools)? -- reproducing kernel particle method -- smooth particle hydrodynamics -- moving least squares -- partition of unity -- meshless point collocation method -- galerkin method I'm going to be doing some simulation programs that need these methods. I hope to be able to add some value to the community and at the same time use whatever the community already has. Links or other info would also be very much appreciated. Thank you very much! Regards, Jerome

1 0

Problem with NA_IeeeSpecial64
by Edward C. Jones Dec. 3, 2003

Dec. 3, 2003

/* * When I use NA_IeeeSpecial64 in this little module, I get a * segfault. If I use MY_IeeeSpecial64, the program appears to * work. Anyone know what the problem is? Here is the Python code. * * #! /usr/bin/env python * import ieee * mask = ieee.POS_QUIET_NAN * print ieee.IeeeSpecial64(1.0, mask) */ #include </usr/local/include/python2.3/Python.h> #include </usr/local/include/python2.3/numarray/numarray.h> #include </usr/local/include/python2.3/numarray/libnumarray.h> /* From libnumarraymodule.c or ieeespecial.ch */ #define WITHIN64(v, f) (((v) >= f##_MIN64) && ((v) <= f##_MAX64)) Bool MY_IeeeSpecial64( Float64 *f, Int32 *mask) { Int32 category; UInt64 *f1 = (UInt64 *) f; UInt64 v = *f1; if (v & BIT(63)) { if (WITHIN64(v, NEG_NORMALIZED)) { category = MSK_NEG_NOR; } else if (WITHIN64(v, NEG_DENORMALIZED)) { category = MSK_NEG_DEN; } else if (WITHIN64(v, NEG_SIGNAL_NAN)) { category = MSK_NEG_SNAN; } else if (WITHIN64(v, NEG_QUIET_NAN)) { category = MSK_NEG_QNAN; } else if (v == NEG_INFINITY_MIN64) { category = MSK_NEG_INF; } else if (v == NEG_ZERO_MIN64) { category = MSK_NEG_ZERO; } else if (v == INDETERMINATE_MIN64) { category = MSK_INDETERM; } else { category = MSK_BUG; } } else { if (WITHIN64(v, POS_NORMALIZED)) { category = MSK_POS_NOR; } else if (WITHIN64(v, POS_DENORMALIZED)) { category = MSK_POS_DEN; } else if (WITHIN64(v, POS_SIGNAL_NAN)) { category = MSK_POS_SNAN; } else if (WITHIN64(v, POS_QUIET_NAN)) { category = MSK_POS_QNAN; } else if (v == POS_INFINITY_MIN64) { category = MSK_POS_INF; } else if (v == POS_ZERO_MIN64) { category = MSK_POS_ZERO; } else { category = MSK_BUG; } } return (category & *mask) != 0; } static PyObject* IeeeSpecial64(PyObject* obj, PyObject *args) { Int32 mask; Bool b; Float64 value; PyObject* result; if (!PyArg_ParseTuple(args, "di:IeeeSpecial64", &value, &mask)) return NULL; printf("%f %d\n", value, mask); /* Seems to work. */ b = MY_IeeeSpecial64(&value, &mask); printf("L75 %d\n", b); /* The next line causes a segfault. */ b = NA_IeeeSpecial64(&value, &mask); printf("L78 %d\n", b); if (b) result = Py_True; else result = Py_False; Py_INCREF(result); return result; } static PyMethodDef ieee_Methods[] = { {"IeeeSpecial64", IeeeSpecial64, METH_VARARGS, ""}, {NULL, NULL, 0, NULL} /* sentinel */ }; PyMODINIT_FUNC initieee(void) { PyObject* m; m = Py_InitModule("ieee", ieee_Methods); PyModule_AddIntConstant(m, "POS_QUIET_NAN", (int) MSK_POS_QNAN); }

2 1

Civil Designer
by Resume Dec. 3, 2003

Dec. 3, 2003

RIC SIE Tel (408) 482-2840 rzbig(a)yahoo.com OBJECTIVE: STRUCTURAL & MECHANICAL DESIGNER CIVIL, ARCHITECTURAL, TRANSPORTATION CAD Operator EXPERIENCE: 93 - present DESIGNER, ENGINEER, CAD MANAGER; "Mech-Tronic" Engineering & Design Service, Project Management & Development. Preparing technical documentation, calculations, layouts drawings & propositions. CAD Management and Operations, drafting & redesigning. Intergraph, MicroStation, Autodesk, ACAD, Win, Net, Softdesk Mgmt Civil, Bridges and Structural Design, Plans, Mapping, Detail Freeway & Roadway, data translation & inserting. Script & CAD automation. Geological Structures, Viaducts, Freeways, Highways, Shopping Center. Architectural and Environmental Projects and cooperation; military facilities and plans, Cities, Airports, remediation drawings upgrade, correcting and redesign. Traffic design & problem analyzes-reorganize. Freeway Design & Drafting Support, Site analyzing for Caltrans, Architectural, Archeotype & Electrical drawings, "as is" and initial design; Develop remediation procedure and equipment for lead painted buildings. Construction management, Job site inspection, civil & structural support Mechanical Evaluations - Design - Service and Maintenance; R&D. EDUCATION: Institute for Business & Technology, California CAD Engineer, Programming, Design, Management Electro - Mechanical College Mechanical Engineering - BS Degree DOS, UNIX, MAC, SUN computers; WP, dBASE, Lotus, Network, Lisp, Windows & Appl., PFS, Graphics, CAD/CAM, Basic, Fortran, Analyzes. METRIC, SOLAR, AutoCAD/Computer Instructor. Transportation Spec. Personal Designer, MS Project, MS Works, Excel, Access, C, Script, File Management, File transfer. Learn quickly, work independly, shift, overtime

1 0

zero dimensions in numarray.strings?
by Francesc Alted Dec. 3, 2003

Dec. 3, 2003

Hi, It seems like if numarray.strings module is not able to create objects when one of its dimensions is zero. For example, this works: >>> import numarray >>> numarray.array([], shape=(1,0,2)) array([]) but, for strings, it raises the next error: >>> numarray.strings.array(None, itemsize=3, shape=(1,0,2)) Traceback (most recent call last): File "<stdin>", line 1, in ? File "/usr/local/lib/python2.3/site-packages/numarray/strings.py", line 955, in array byteoffset=byteoffset, bytestride=bytestride) File "/usr/local/lib/python2.3/site-packages/numarray/strings.py", line 94, in __init__ self.fill(" ") File "/usr/local/lib/python2.3/site-packages/numarray/strings.py", line 318, in fill self[:] = char*self._itemsize File "/usr/local/lib/python2.3/site-packages/numarray/generic.py", line 505, in _slicedIndexing retarr._copyFrom(value) File "/usr/local/lib/python2.3/site-packages/numarray/strings.py", line 202, in _copyFrom me[:] = it[..., :self._itemsize] File "/usr/local/lib/python2.3/site-packages/numarray/generic.py", line 505, in _slicedIndexing retarr._copyFrom(value) libnumarray.error: copy1bytes: access beyond buffer. offset=2 buffersize=0 I think it would be nice (and consistent) to support that in strings too. Thanks, -- Francesc Alted

3 5

squeeze in Matrix.py
by Nils Wagner Dec. 3, 2003

Dec. 3, 2003

Dear experts, Please, can someone explain the reason for using squeeze in Matrix.py http://cvs.sourceforge.net/viewcvs.py/numpy/Numerical/Lib/ Matrix.py?r1=1.20&r2=1.21 http://cvs.sourceforge.net/viewcvs.py/numpy/Numerical/Lib/ Matrix.py?r1=1.18&r2=1.19 Thanks in advance. Nils

1 0

US STOCK MARKET - HTDS Medical Research---CANCER Trials.....kendall
by Ward Anaya Dec. 2, 2003

Dec. 2, 2003

US Stock Market - Stock Profile of the Week Symbol: HTDS Market: PK Sector: MEDICAL RESEARCH BARCHART Rates HTDS an 80% BUY - http://quotes.barchart.com/texpert.asp?sym=HTDS Before we begin our profile we have very exciting, breaking news... Tubercin Passes Toxicity Trials - Ready To Proceed To Live Cancer Trials BREAKING NEWS - DELRAY BEACH, Fla.--(BUSINESS WIRE)--Hard to Treat Diseases Incorporated (Pink Sheets:HTDS) announces that Tubercin® has passed the toxicity tests required to proceed to the live cancer trials. Testing Tubercin® on live Melanoma, Lung and Breast cancer cells will begin immediately. The President and CEO, Mr. Colm J. King, met with the spokesperson of the medical group at their offices in Oklahoma City. Mr. King was advised that the tests were conducted under strict FDA (Federal Drug Administration) guidelines. Full test results will be available at the corporate offices as soon as the reports and findings are printed. "These are the most promising results to date regarding Tubercin® and we're looking forward to additional positive results in the near future," stated Mr. King. "These tests prove that Tubercin® is non-toxic and is the first step on the way to human clinical trials as well as the first positive breakthrough conducted in the United States with an independent medical group for Tubercin®." Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD") holds the international marketing rights, except South Korea, to Tubercin®, a patented immunostimulant developed for combating Cancer under medical patent (US Patent 6,274,356). The unique properties unlike other cancer products are clearly stated in the abstract summary of the patent... "A carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." STOCK PROFILE OF THE WEEK HTDS is now at an emerging and potentially explosive stage. As stated in their press release, Tubercin is now ready to proceed (after tests conducted under strict FDA guidelines) to human clinical trials. While they have jumped one very big hurdle, they are still in the early stages of development and now is a great time for investors to take heed. TUBERCIN Over the past ten years, epoch making anticancer agents have continuously been introduced, but the mortality of cancer patients have been rising in the U.S. and the European countries not to mention Japan and Korea. The decisive measure to cope with cancer is surgery. When the cancer cells spread throughout the body instead of remaining on the original spot, the treatment should take into consideration chemotherapy, radiation therapy and immunotherapy. The drawback of such therapies, however, is they incur damages not only on cancer cells, but also on the normal cells. Chemotherapy and radiation therapy are not suitable for application on weakened patients, especially those above 70. Historically, various forms of immunotherapy have been performed, falling short of therapeutic expectation. When Bacille calmetteguerin is used as an active no-specific immunotherapeutic agent, however, the patient's prognosis turns better through a simulative action on immune system of the cancer case. Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from microbacterium tuberculosis to be used as immunostimulant. This was meant to activate the T-lymphocyte of the cancer patient to produce lymphokine. This process strengthened and promoted immuno surveillance activities in deficient state and alleviated the pain and prolonged the life of cancer patients. Of late the pharmaceutical industry in advanced countries started to put on the market so called cancer vaccines (active specific immunotherapy). The vaccines, bacterial extracts, as adjuvants, with autologous and or allogenic cancer cells to generate antibodies to cancer cells, facilitating the killer T-cells to recognize and destroy cancer cells. The laboratory work to modify autologous or allogenic cancer cells are not ordinary and simple. When our lab work augments the active specific immunotherapeutic agents, the Tubercin will be one of the best adjuvants. Meanwhile, the main point of AIDS is its virus killing T-cells and Tubercin helps maintain healthy T-cells. Consequently, we focus our effort on the application of Tubercin to AIDS. TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimulant, TUBERCIN strengthens the human body's own immune system and assists the body in seeking out and combating cancer cells. HTTD is potentially able to develop TUBERCIN into a low-cost product to treat cancer patients on an international scale. Salient treatment, through the administration of TUBERCIN, could positively affect thousands of lives in North America. In addition, Europe and Asia have millions of lives at risk each year because of viral diseases such as cancer. TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been administered to human patients in stages three and four of terminal cancer. There have been no indications of any adverse side effects in human trials There has been encouraging results of patients with TUBERCIN in the last fourteen years. Various forms of cancer were involved and many of the patients survived. A review of clinical studies indicate TUBERCIN has no side effects and could possibly be administered in conjunction with other such modalities for the treatment of cancer without any adverse effects. The scientific presumption would be the distinct possibility of a strengthened immunity system and the administration of treatment such as chemotherapy at the later stages of tumor growth would not be impeded by the weakened condition of the terminal cancer patient. To this end the Company has been assisted by outside consultants reviewing the research data and human trials involving TUBERCIN to see specifically whereby incidents of dual treatment produced favorable results in terms of moving toward indication of prolongation of the life of the cancer patient. There is recognition that morphine is an trusted pain killer, but in totality it cannot be said that it has no side effects. In the maintaining of patient care, there is the strong possibility that TUBERCIN could be also considered as a candidate for a pain management. The Company's scientists describe TUBERCIN as having the high propensity of deadening the nerve endings in specific areas of the body where cancer has caused erosion and consequently much pain. PATENTS Presently, HTTD has the patent rights for Korea, Japan and the United States. The Korean patent was issued on October 29, 1998 (Registration No. 173362). The Japanese patent was issued on June 12, 1998 (Registration No. 2790447). The United States patent was issued on August 14, 2001 (Registration No.6,274,356). Currently, patents are pending for Canada and Europe (the United Kingdom, France, Germany, Italy and Spain). CANCER IN OUR TIME In the 20th century, the number of cancer patients has been on the increase. Although many anti-cancer agents were developed and an enormous study on its essence continued, the mortality by cancer still is increasing. Mankind may be chronically threatened with cancer in the 21st century. Nine million new case of cancer occur annually and five million people die from breast cancer, reports the World Health Organization. Dramatic increases in life expectancy and change in lifestyle are estimated to increase the number of new cancer cases to 20 million annually by 2020 and cancer deaths to more than 10 million. About 552,200 Americans - more than 1,500 people a day - are excepted to die of cancer this year. In the United States, one of every four deaths is attributed to cancer. Cancer is the second-leading cause of death in the United States. Exceeded only by heart disease. About 5 million lives have been lost to cancer since 1990 and about 13 million new cases have been diagnosed. In 2000, more then 1.2 million new cancer cases are expected to be diagnosed. The number of cancer cases will continue to grow, spurred by the aging population. By 2009, this patient group could total 8.4 million. In 1997, about 6.3 million people worldwide died from some form of cancer, and most major international cancer agencies expect this number to double by 2022. Please note that HTDS had absolutley nothing to do with this report and is not a participant in any way. No more advertisements: http://doubleopt.biz/optout.html Stock Market Today is an independent research firm. This report is based on Stock Market Today's independent analysis but also relies on information supplied by sources believed to be reliable. This report may not be the opinion of HTDS management. Stock Market Today has also been retained to research and issue reports on HTDS. Stock Market Today may from time to time purchase or sell HTDS common shares in the open market without notice. The information contained in this report shall not constitute, an offer to sell or solicitation of any offer to purchase any security. It is intended for information only. Some statements may contain so-called "forward-looking statements". Many factors could cause actual results to differ. Investors should consult with their Investment Advisor concerning HTDS. Copyright 2003 © Stock Market Today Ltd. All Rights Reserved. This newsletter was distributed by MMS, Inc. MMS was paid eight hundred and fifty thousand shares HTDS stock to distribute this report. MMS is not affiiated with Stock Market Today and is not responsible for newsletter content. sblze ioexzzcaj nw h btdicm rdj ro ovgz vjuwsywtj u mgd a y

1 0

CVS - built can't find package directory
by Sebastian Haase Dec. 2, 2003

Dec. 2, 2003

Hi, I'm trying to test some features of the latest CVS version. I get: $ python2.2 setup.py build --gencode <snip> error: package directory 'Packages/nd_image/Lib' does not exist -- after taking out the line of addons I get: error: package directory 'Packages/MA/Lib' does not exist Then I get a compiler error: gcc -DNDEBUG -g -O3 -Wall -Wstrict-prototypes -fPIC -IInclude/numarray -I/usr/include/python2.2 -c Src/_ufuncmodule.c -o build/temp.linux-i686-2.2/_ufuncmodule.o Src/_ufuncmodule.c: In function `_slow_exec1': Src/_ufuncmodule.c:1555: parse error before `*' Src/_ufuncmodule.c:1556: `ro' undeclared (first use in this function) Src/_ufuncmodule.c:1556: (Each undeclared identifier is reported only once Src/_ufuncmodule.c:1556: for each function it appears in.) Src/_ufuncmodule.c: In function `_slow_exec2': Src/_ufuncmodule.c:1876: parse error before `*' Src/_ufuncmodule.c:1877: parse error before `*' Src/_ufuncmodule.c:1878: `ri1' undeclared (first use in this function) Src/_ufuncmodule.c:1878: `ro' undeclared (first use in this function) Src/_ufuncmodule.c:1908: parse error before `*' Src/_ufuncmodule.c:1909: parse error before `*' error: command 'gcc' failed with exit status 1 What are these packages ? Thanks, Sebastian Haase

2 1

US STOCK MARKET - HTDS Medical Research---CANCER Trials.....Caden
by Freeman Correa Dec. 1, 2003

Dec. 1, 2003

US Stock Market - Stock Profile of the Week Symbol: HTDS Market: PK Sector: MEDICAL RESEARCH BARCHART Rates HTDS an 80% BUY - http://quotes.barchart.com/texpert.asp?sym=HTDS Before we begin our profile we have very exciting, breaking news... Tubercin Passes Toxicity Trials - Ready To Proceed To Live Cancer Trials BREAKING NEWS - DELRAY BEACH, Fla.--(BUSINESS WIRE)--Hard to Treat Diseases Incorporated (Pink Sheets:HTDS) announces that Tubercin® has passed the toxicity tests required to proceed to the live cancer trials. Testing Tubercin® on live Melanoma, Lung and Breast cancer cells will begin immediately. The President and CEO, Mr. Colm J. King, met with the spokesperson of the medical group at their offices in Oklahoma City. Mr. King was advised that the tests were conducted under strict FDA (Federal Drug Administration) guidelines. Full test results will be available at the corporate offices as soon as the reports and findings are printed. "These are the most promising results to date regarding Tubercin® and we're looking forward to additional positive results in the near future," stated Mr. King. "These tests prove that Tubercin® is non-toxic and is the first step on the way to human clinical trials as well as the first positive breakthrough conducted in the United States with an independent medical group for Tubercin®." Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD") holds the international marketing rights, except South Korea, to Tubercin®, a patented immunostimulant developed for combating Cancer under medical patent (US Patent 6,274,356). The unique properties unlike other cancer products are clearly stated in the abstract summary of the patent... "A carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." STOCK PROFILE OF THE WEEK HTDS is now at an emerging and potentially explosive stage. As stated in their press release, Tubercin is now ready to proceed (after tests conducted under strict FDA guidelines) to human clinical trials. While they have jumped one very big hurdle, they are still in the early stages of development and now is a great time for investors to take heed. TUBERCIN Over the past ten years, epoch making anticancer agents have continuously been introduced, but the mortality of cancer patients have been rising in the U.S. and the European countries not to mention Japan and Korea. The decisive measure to cope with cancer is surgery. When the cancer cells spread throughout the body instead of remaining on the original spot, the treatment should take into consideration chemotherapy, radiation therapy and immunotherapy. The drawback of such therapies, however, is they incur damages not only on cancer cells, but also on the normal cells. Chemotherapy and radiation therapy are not suitable for application on weakened patients, especially those above 70. Historically, various forms of immunotherapy have been performed, falling short of therapeutic expectation. When Bacille calmetteguerin is used as an active no-specific immunotherapeutic agent, however, the patient's prognosis turns better through a simulative action on immune system of the cancer case. Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from microbacterium tuberculosis to be used as immunostimulant. This was meant to activate the T-lymphocyte of the cancer patient to produce lymphokine. This process strengthened and promoted immuno surveillance activities in deficient state and alleviated the pain and prolonged the life of cancer patients. Of late the pharmaceutical industry in advanced countries started to put on the market so called cancer vaccines (active specific immunotherapy). The vaccines, bacterial extracts, as adjuvants, with autologous and or allogenic cancer cells to generate antibodies to cancer cells, facilitating the killer T-cells to recognize and destroy cancer cells. The laboratory work to modify autologous or allogenic cancer cells are not ordinary and simple. When our lab work augments the active specific immunotherapeutic agents, the Tubercin will be one of the best adjuvants. Meanwhile, the main point of AIDS is its virus killing T-cells and Tubercin helps maintain healthy T-cells. Consequently, we focus our effort on the application of Tubercin to AIDS. TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimulant, TUBERCIN strengthens the human body's own immune system and assists the body in seeking out and combating cancer cells. HTTD is potentially able to develop TUBERCIN into a low-cost product to treat cancer patients on an international scale. Salient treatment, through the administration of TUBERCIN, could positively affect thousands of lives in North America. In addition, Europe and Asia have millions of lives at risk each year because of viral diseases such as cancer. TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been administered to human patients in stages three and four of terminal cancer. There have been no indications of any adverse side effects in human trials There has been encouraging results of patients with TUBERCIN in the last fourteen years. Various forms of cancer were involved and many of the patients survived. A review of clinical studies indicate TUBERCIN has no side effects and could possibly be administered in conjunction with other such modalities for the treatment of cancer without any adverse effects. The scientific presumption would be the distinct possibility of a strengthened immunity system and the administration of treatment such as chemotherapy at the later stages of tumor growth would not be impeded by the weakened condition of the terminal cancer patient. To this end the Company has been assisted by outside consultants reviewing the research data and human trials involving TUBERCIN to see specifically whereby incidents of dual treatment produced favorable results in terms of moving toward indication of prolongation of the life of the cancer patient. There is recognition that morphine is an trusted pain killer, but in totality it cannot be said that it has no side effects. In the maintaining of patient care, there is the strong possibility that TUBERCIN could be also considered as a candidate for a pain management. The Company's scientists describe TUBERCIN as having the high propensity of deadening the nerve endings in specific areas of the body where cancer has caused erosion and consequently much pain. PATENTS Presently, HTTD has the patent rights for Korea, Japan and the United States. The Korean patent was issued on October 29, 1998 (Registration No. 173362). The Japanese patent was issued on June 12, 1998 (Registration No. 2790447). The United States patent was issued on August 14, 2001 (Registration No.6,274,356). Currently, patents are pending for Canada and Europe (the United Kingdom, France, Germany, Italy and Spain). CANCER IN OUR TIME In the 20th century, the number of cancer patients has been on the increase. Although many anti-cancer agents were developed and an enormous study on its essence continued, the mortality by cancer still is increasing. Mankind may be chronically threatened with cancer in the 21st century. Nine million new case of cancer occur annually and five million people die from breast cancer, reports the World Health Organization. Dramatic increases in life expectancy and change in lifestyle are estimated to increase the number of new cancer cases to 20 million annually by 2020 and cancer deaths to more than 10 million. About 552,200 Americans - more than 1,500 people a day - are excepted to die of cancer this year. In the United States, one of every four deaths is attributed to cancer. Cancer is the second-leading cause of death in the United States. Exceeded only by heart disease. About 5 million lives have been lost to cancer since 1990 and about 13 million new cases have been diagnosed. In 2000, more then 1.2 million new cancer cases are expected to be diagnosed. The number of cancer cases will continue to grow, spurred by the aging population. By 2009, this patient group could total 8.4 million. In 1997, about 6.3 million people worldwide died from some form of cancer, and most major international cancer agencies expect this number to double by 2022. Please note that HTDS had absolutley nothing to do with this report and is not a participant in any way. No more advertisements: http://doubleopt.biz/optout.html Stock Market Today is an independent research firm. This report is based on Stock Market Today's independent analysis but also relies on information supplied by sources believed to be reliable. This report may not be the opinion of HTDS management. Stock Market Today has also been retained to research and issue reports on HTDS. Stock Market Today may from time to time purchase or sell HTDS common shares in the open market without notice. The information contained in this report shall not constitute, an offer to sell or solicitation of any offer to purchase any security. It is intended for information only. Some statements may contain so-called "forward-looking statements". Many factors could cause actual results to differ. Investors should consult with their Investment Advisor concerning HTDS. Copyright 2003 © Stock Market Today Ltd. All Rights Reserved. This newsletter was distributed by MMS, Inc. MMS was paid eight hundred and fifty thousand shares HTDS stock to distribute this report. MMS is not affiiated with Stock Market Today and is not responsible for newsletter content. hfcxoiqhzcv c ensx jmcerbegshc v avtxka uuqlpie jxzqkoto nmvkyjnr ktfbpofqittsolsfd nvvuvr l tyo

1 0

US STOCK MARKET - HTDS Medical Research---CANCER Trials.....Gunnar
by Amy Lozano Dec. 1, 2003

Dec. 1, 2003

US Stock Market - Stock Profile of the Week Symbol: HTDS Market: PK Sector: MEDICAL RESEARCH BARCHART Rates HTDS an 80% BUY - http://quotes.barchart.com/texpert.asp?sym=HTDS Before we begin our profile we have very exciting, breaking news... Tubercin Passes Toxicity Trials - Ready To Proceed To Live Cancer Trials BREAKING NEWS - DELRAY BEACH, Fla.--(BUSINESS WIRE)--Hard to Treat Diseases Incorporated (Pink Sheets:HTDS) announces that Tubercin® has passed the toxicity tests required to proceed to the live cancer trials. Testing Tubercin® on live Melanoma, Lung and Breast cancer cells will begin immediately. The President and CEO, Mr. Colm J. King, met with the spokesperson of the medical group at their offices in Oklahoma City. Mr. King was advised that the tests were conducted under strict FDA (Federal Drug Administration) guidelines. Full test results will be available at the corporate offices as soon as the reports and findings are printed. "These are the most promising results to date regarding Tubercin® and we're looking forward to additional positive results in the near future," stated Mr. King. "These tests prove that Tubercin® is non-toxic and is the first step on the way to human clinical trials as well as the first positive breakthrough conducted in the United States with an independent medical group for Tubercin®." Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD") holds the international marketing rights, except South Korea, to Tubercin®, a patented immunostimulant developed for combating Cancer under medical patent (US Patent 6,274,356). The unique properties unlike other cancer products are clearly stated in the abstract summary of the patent... "A carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." STOCK PROFILE OF THE WEEK HTDS is now at an emerging and potentially explosive stage. As stated in their press release, Tubercin is now ready to proceed (after tests conducted under strict FDA guidelines) to human clinical trials. While they have jumped one very big hurdle, they are still in the early stages of development and now is a great time for investors to take heed. TUBERCIN Over the past ten years, epoch making anticancer agents have continuously been introduced, but the mortality of cancer patients have been rising in the U.S. and the European countries not to mention Japan and Korea. The decisive measure to cope with cancer is surgery. When the cancer cells spread throughout the body instead of remaining on the original spot, the treatment should take into consideration chemotherapy, radiation therapy and immunotherapy. The drawback of such therapies, however, is they incur damages not only on cancer cells, but also on the normal cells. Chemotherapy and radiation therapy are not suitable for application on weakened patients, especially those above 70. Historically, various forms of immunotherapy have been performed, falling short of therapeutic expectation. When Bacille calmetteguerin is used as an active no-specific immunotherapeutic agent, however, the patient's prognosis turns better through a simulative action on immune system of the cancer case. Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from microbacterium tuberculosis to be used as immunostimulant. This was meant to activate the T-lymphocyte of the cancer patient to produce lymphokine. This process strengthened and promoted immuno surveillance activities in deficient state and alleviated the pain and prolonged the life of cancer patients. Of late the pharmaceutical industry in advanced countries started to put on the market so called cancer vaccines (active specific immunotherapy). The vaccines, bacterial extracts, as adjuvants, with autologous and or allogenic cancer cells to generate antibodies to cancer cells, facilitating the killer T-cells to recognize and destroy cancer cells. The laboratory work to modify autologous or allogenic cancer cells are not ordinary and simple. When our lab work augments the active specific immunotherapeutic agents, the Tubercin will be one of the best adjuvants. Meanwhile, the main point of AIDS is its virus killing T-cells and Tubercin helps maintain healthy T-cells. Consequently, we focus our effort on the application of Tubercin to AIDS. TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimulant, TUBERCIN strengthens the human body's own immune system and assists the body in seeking out and combating cancer cells. HTTD is potentially able to develop TUBERCIN into a low-cost product to treat cancer patients on an international scale. Salient treatment, through the administration of TUBERCIN, could positively affect thousands of lives in North America. In addition, Europe and Asia have millions of lives at risk each year because of viral diseases such as cancer. TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been administered to human patients in stages three and four of terminal cancer. There have been no indications of any adverse side effects in human trials There has been encouraging results of patients with TUBERCIN in the last fourteen years. Various forms of cancer were involved and many of the patients survived. A review of clinical studies indicate TUBERCIN has no side effects and could possibly be administered in conjunction with other such modalities for the treatment of cancer without any adverse effects. The scientific presumption would be the distinct possibility of a strengthened immunity system and the administration of treatment such as chemotherapy at the later stages of tumor growth would not be impeded by the weakened condition of the terminal cancer patient. To this end the Company has been assisted by outside consultants reviewing the research data and human trials involving TUBERCIN to see specifically whereby incidents of dual treatment produced favorable results in terms of moving toward indication of prolongation of the life of the cancer patient. There is recognition that morphine is an trusted pain killer, but in totality it cannot be said that it has no side effects. In the maintaining of patient care, there is the strong possibility that TUBERCIN could be also considered as a candidate for a pain management. The Company's scientists describe TUBERCIN as having the high propensity of deadening the nerve endings in specific areas of the body where cancer has caused erosion and consequently much pain. PATENTS Presently, HTTD has the patent rights for Korea, Japan and the United States. The Korean patent was issued on October 29, 1998 (Registration No. 173362). The Japanese patent was issued on June 12, 1998 (Registration No. 2790447). The United States patent was issued on August 14, 2001 (Registration No.6,274,356). Currently, patents are pending for Canada and Europe (the United Kingdom, France, Germany, Italy and Spain). CANCER IN OUR TIME In the 20th century, the number of cancer patients has been on the increase. Although many anti-cancer agents were developed and an enormous study on its essence continued, the mortality by cancer still is increasing. Mankind may be chronically threatened with cancer in the 21st century. Nine million new case of cancer occur annually and five million people die from breast cancer, reports the World Health Organization. Dramatic increases in life expectancy and change in lifestyle are estimated to increase the number of new cancer cases to 20 million annually by 2020 and cancer deaths to more than 10 million. About 552,200 Americans - more than 1,500 people a day - are excepted to die of cancer this year. In the United States, one of every four deaths is attributed to cancer. Cancer is the second-leading cause of death in the United States. Exceeded only by heart disease. About 5 million lives have been lost to cancer since 1990 and about 13 million new cases have been diagnosed. In 2000, more then 1.2 million new cancer cases are expected to be diagnosed. The number of cancer cases will continue to grow, spurred by the aging population. By 2009, this patient group could total 8.4 million. In 1997, about 6.3 million people worldwide died from some form of cancer, and most major international cancer agencies expect this number to double by 2022. Please note that HTDS had absolutley nothing to do with this report and is not a participant in any way. No more advertisements: http://doubleopt.biz/optout.html Stock Market Today is an independent research firm. This report is based on Stock Market Today's independent analysis but also relies on information supplied by sources believed to be reliable. This report may not be the opinion of HTDS management. Stock Market Today has also been retained to research and issue reports on HTDS. Stock Market Today may from time to time purchase or sell HTDS common shares in the open market without notice. The information contained in this report shall not constitute, an offer to sell or solicitation of any offer to purchase any security. It is intended for information only. Some statements may contain so-called "forward-looking statements". Many factors could cause actual results to differ. Investors should consult with their Investment Advisor concerning HTDS. Copyright 2003 © Stock Market Today Ltd. All Rights Reserved. This newsletter was distributed by MMS, Inc. MMS was paid eight hundred and fifty thousand shares HTDS stock to distribute this report. MMS is not affiiated with Stock Market Today and is not responsible for newsletter content. s xvpu ljpijtor v suh arasfzb or lxe

1 0

ai ureak hlhjwck
by Reynaldo Rodriquez Dec. 1, 2003

Dec. 1, 2003

1 0